NCT02232906 - Switch From Oral Iron to Intravenous Ferric Carboxymaltose in Non-dialysis Chronic Kidney Disease (CKD) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

September 30, 2013

Study Completion Date

September 30, 2013

Conditions

Iron DeficiencyAnaemia

Interventions

DRUG

intravenous ferric carboxymaltose

Ferric carboxymaltose (FCM) dose of 1,000 mg iron, followed by a 6-month ESA/FCM maintenance regimen (target: Hemoglobin 120 g/L, transferrin saturation \>20%)

Trial Locations (1)

1118

Hospital Alemán, Buenos Aires